Detection of Fusobacterium nucleatum in stool and colonic tissues from Norwegian colorectal cancer patients
Norway has one of the world’s highest incidences of colorectal cancer (CRC). Accumulating research suggests that the intestinal microbiota may have an important role in initiation and progression of colorectal cancer. In order to evaluate microbiome-based biomarkers for non-invasive detection of CRC, the levels of Fusobacterium nucleatum and selected Escherichia coli toxin genes in stool and mucosa from a small cohort of Norwegian patients were investigated. The study cohort included 72 patients scheduled for colonoscopy. The patients were divided into three groups upon their examinations: cancer, polyp, and control groups. Levels of F. nucleatum in stool samples were significantly higher in the cancer group compared with the control group and the polyp group. High levels of F. nucleatum in stool reflected detection of F. nucleatum in the tumor tissues of colorectal cancer patients. However, no difference in the levels of E. coli toxin genes in neither stool nor biopsy samples between the patient groups was observed. This study suggests that a quantitative PCR assay targeting F. nucleatum in stool samples has the potential to be included in a larger panel of biomarkers for non-invasive testing for colorectal cancer.
KeywordsCRC Fusobacterium nucleatum Early detection Non-invasive Biomarker qPCR
Students at Oslo Metropolitan University (Mia Sandgren et al., Sammy Ramstock et al., and Silje Mathiassen et al.) have contributed to parts of the contents in this manuscript. We thank the Pathology Dept. at Akershus University Hospital for characterization of tumors. We also express our gratitude to biomedical laboratory scientist Eva Smedsrud, Dept. of Multidisciplinary Laboratory Science and Medical Biochemistry, Genetic Unit, for all help with patient inclusion and sample processing.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
The regional committee for medical and health-related research ethics (REK 2012/1944) and the data protection manager at Ahus have approved the study. Written informed consent was obtained from all participants.
- 9.Ma CT, Luo HS, Gao F, Tang QC, Chen W (2018) Fusobacterium nucleatum promotes the progression of colorectal cancer by interacting with E-cadherin. Oncol Lett 16(2):2606–2612Google Scholar
- 25.Noone JC, Bemanian V, Smith Tunsjø H (2017) DNA-ekstraksjon: Mengde er ikke synonymt med mangfold. Bioingeniøren 6:20–26Google Scholar
- 27.Muller D, Greune L, Heusipp G, Karch H, Fruth A, Tschape H et al (2007) Identification of unconventional intestinal pathogenic Escherichia coli isolates expressing intermediate virulence factor profiles by using a novel single-step multiplex PCR. Appl Environ Microbiol 73(10):3380–3390CrossRefGoogle Scholar
- 33.Iacopetta B (2001) Are there two sides to colorectal cancer? Int J Cancer 101(5):403–408Google Scholar